ALX Oncology Ownership 2024 | Who Owns ALX Oncology Now?
Institutional Ownership
96.44%
Insider Ownership
1.92%
Retail Ownership
1.65%
Institutional Holders
110.00
ALX Oncology Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VENBIO PARTNERS LLC | 19.35% | 25.26% | 9,699,925 | - | - | 58,490,548 | Jun 30, 2024 |
| FMR LLC | 15.59% | 0.00% | 7,814,996 | 292,184 | 3.88% | 47,124,426 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 8.42% | 2.35% | 4,220,048 | - | - | 25,446,889 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 8.05% | 1.47% | 4,036,451 | -290,058 | -6.70% | 24,339,800 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 7.18% | 1.62% | 3,600,000 | 990,000 | 37.93% | 21,708,000 | Jun 30, 2024 |
| BLACKROCK INC. | 5.36% | 0.00% | 2,687,619 | 466,058 | 20.98% | 16,206,343 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 4.35% | 2.04% | 2,180,864 | 912,393 | 71.93% | 13,150,610 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 3.78% | 0.23% | 1,894,462 | -823,508 | -30.30% | 11,423,606 | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.45% | 0.00% | 1,727,248 | 160,784 | 10.26% | 10,415,306 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 3.14% | 0.36% | 1,575,605 | 1,575,605 | 100.00% | 9,500,898 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 2.64% | 0.00% | 1,325,196 | 1,265,006 | 2101.69% | 7,990,932 | Jun 30, 2024 |
| STATE STREET CORP | 1.41% | 0.00% | 705,547 | 151,680 | 27.39% | 4,254,448,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.40% | 0.00% | 700,406 | 95,692 | 15.82% | 4,224,247 | Jun 30, 2024 |
| MORGAN STANLEY | 1.34% | 0.00% | 673,358 | 330,221 | 96.24% | 4,060,355 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 1.27% | 0.01% | 635,679 | 514,133 | 422.99% | 3,833,144 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.87% | 0.00% | 438,200 | 204,100 | 87.19% | 2,642,346 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT B.V. | 0.79% | 0.58% | 396,966 | 396,966 | 100.00% | 2,270,646 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.61% | 0.04% | 307,529 | 307,529 | 100.00% | 1,854,400 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.61% | 0.00% | 304,100 | 304,100 | 100.00% | 1,833,725 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.58% | 0.00% | 292,226 | 226,771 | 346.45% | 1,762,123 | Jun 30, 2024 |
ALX Oncology's largest institutional shareholder is VENBIO PARTNERS LLC, holding 19.35% of the company's total share outstanding, currently valued at $58.49M. The top 10 institutional shareholders own together 78.68% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VENBIO PARTNERS LLC | 19.35% | 25.26% | 9,699,925 | - | - | 58,490,548 | Jun 30, 2024 |
| VIVO CAPITAL, LLC | 8.42% | 2.35% | 4,220,048 | - | - | 25,446,889 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 4.35% | 2.04% | 2,180,864 | 912,393 | 71.93% | 13,150,610 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 7.18% | 1.62% | 3,600,000 | 990,000 | 37.93% | 21,708,000 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 8.05% | 1.47% | 4,036,451 | -290,058 | -6.70% | 24,339,800 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT B.V. | 0.79% | 0.58% | 396,966 | 396,966 | 100.00% | 2,270,646 | Jun 30, 2024 |
| PARADIGM BIOCAPITAL ADVISORS LP | 3.14% | 0.36% | 1,575,605 | 1,575,605 | 100.00% | 9,500,898 | Jun 30, 2024 |
| NAN FUNG GROUP HOLDINGS LTD | 0.08% | 0.27% | 41,950 | - | - | 252,959 | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 3.78% | 0.23% | 1,894,462 | -823,508 | -30.30% | 11,423,606 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 0.20% | 0.07% | 100,000 | 100,000 | 100.00% | 603,000 | Jun 30, 2024 |
| INSPIRE INVESTING, LLC | 0.12% | 0.04% | 58,707 | 25,551 | 77.06% | 354,003 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.61% | 0.04% | 307,529 | 307,529 | 100.00% | 1,854,400 | Jun 30, 2024 |
| VIRTUS ETF ADVISERS LLC | 0.02% | 0.03% | 10,726 | 4,160 | 63.36% | 64,678 | Jun 30, 2024 |
| SHERBROOKE PARK ADVISERS LLC | 0.04% | 0.02% | 22,172 | 22,172 | 100.00% | 133,697 | Jun 30, 2024 |
| SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 0.15% | 0.02% | 73,468 | -17,489 | -19.23% | 443,012 | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.03% | 0.02% | 16,402 | 16,402 | 100.00% | 98,904 | Jun 30, 2024 |
| QUEST PARTNERS LLC | 0.04% | 0.02% | 20,781 | -4,251 | -16.98% | 125,309 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.28% | 0.02% | 140,000 | 115,194 | 464.38% | 844,200 | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | 0.02% | 0.01% | 10,292 | -148 | -1.42% | 62,061 | Jun 30, 2024 |
| ALGERT GLOBAL LLC | 0.08% | 0.01% | 41,215 | 41,215 | 100.00% | 249,000 | Jun 30, 2024 |
The largest ALX Oncology shareholder by % of total assets is VENBIO PARTNERS LLC. The company owns 9.70M shares of ALX Oncology (ALXO), representing 25.26% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PARADIGM BIOCAPITAL ADVISORS LP | 3.14% | 0.36% | 1,575,605 | 1,575,605 | 100.00% | 9,500,898 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 2.64% | 0.00% | 1,325,196 | 1,265,006 | 2101.69% | 7,990,932 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 7.18% | 1.62% | 3,600,000 | 990,000 | 37.93% | 21,708,000 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 4.35% | 2.04% | 2,180,864 | 912,393 | 71.93% | 13,150,610 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 1.27% | 0.01% | 635,679 | 514,133 | 422.99% | 3,833,144 | Jun 30, 2024 |
| BLACKROCK INC. | 5.36% | 0.00% | 2,687,619 | 466,058 | 20.98% | 16,206,343 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT B.V. | 0.79% | 0.58% | 396,966 | 396,966 | 100.00% | 2,270,646 | Jun 30, 2024 |
| MORGAN STANLEY | 1.34% | 0.00% | 673,358 | 330,221 | 96.24% | 4,060,355 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.61% | 0.04% | 307,529 | 307,529 | 100.00% | 1,854,400 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.61% | 0.00% | 304,100 | 304,100 | 100.00% | 1,833,725 | Jun 30, 2024 |
| FMR LLC | 15.59% | 0.00% | 7,814,996 | 292,184 | 3.88% | 47,124,426 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.46% | 0.01% | 232,022 | 232,022 | 100.00% | 1,399,093 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.58% | 0.00% | 292,226 | 226,771 | 346.45% | 1,762,123 | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 0.87% | 0.00% | 438,200 | 204,100 | 87.19% | 2,642,346 | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | 0.40% | 0.01% | 199,441 | 199,441 | 100.00% | 1,202,629 | Jun 30, 2024 |
| VANGUARD GROUP INC | 3.45% | 0.00% | 1,727,248 | 160,784 | 10.26% | 10,415,306 | Jun 30, 2024 |
| STATE STREET CORP | 1.41% | 0.00% | 705,547 | 151,680 | 27.39% | 4,254,448,000 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.28% | 0.02% | 140,000 | 115,194 | 464.38% | 844,200 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.26% | 0.00% | 130,000 | 100,000 | 333.33% | 783,900 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 0.20% | 0.07% | 100,000 | 100,000 | 100.00% | 603,000 | Jun 30, 2024 |
As of Jun 30 2024, ALX Oncology's largest institutional buyer is PARADIGM BIOCAPITAL ADVISORS LP. The company purchased 1.58M stocks of ALXO, valued at $9.50M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORMORANT ASSET MANAGEMENT, LP | - | - | - | -3,142,079 | -100.00% | - | Jun 30, 2024 |
| ORBIMED ADVISORS LLC | 3.78% | 0.23% | 1,894,462 | -823,508 | -30.30% | 11,423,606 | Jun 30, 2024 |
| REDMILE GROUP, LLC | 8.05% | 1.47% | 4,036,451 | -290,058 | -6.70% | 24,339,800 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.02% | - | 10,622 | -222,147 | -95.44% | 65,000 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 0.00% | - | 2,329 | -199,033 | -98.84% | 14,044,000 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | - | - | - | -160,000 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -106,356 | -100.00% | - | Jun 30, 2024 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | - | - | - | -98,960 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -59,186 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -49,000 | -100.00% | - | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.03% | 0.00% | 13,662 | -46,457 | -77.28% | 82,382 | Jun 30, 2024 |
| MARTINGALE ASSET MANAGEMENT L P | - | - | - | -36,195 | -100.00% | - | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -23,366 | -100.00% | - | Jun 30, 2024 |
| TREXQUANT INVESTMENT LP | - | - | - | -20,990 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
| BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -19,570 | -100.00% | - | Jun 30, 2024 |
| SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 0.15% | 0.02% | 73,468 | -17,489 | -19.23% | 443,012 | Jun 30, 2024 |
| DIMENSIONAL FUND ADVISORS LP | 0.07% | 0.00% | 34,543 | -15,798 | -31.38% | 207,916 | Jun 30, 2024 |
| UBS GROUP AG | 0.03% | - | 15,453 | -13,621 | -46.85% | 93,182 | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -13,000 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, ALX Oncology's biggest institutional seller is CORMORANT ASSET MANAGEMENT, LP. The company sold -3.14M shares of ALXO, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PARADIGM BIOCAPITAL ADVISORS LP | 3.14% | 0.36% | 1,575,605 | 1,575,605 | 100.00% | 9,500,898 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT B.V. | 0.79% | 0.58% | 396,966 | 396,966 | 100.00% | 2,270,646 | Jun 30, 2024 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.61% | 0.04% | 307,529 | 307,529 | 100.00% | 1,854,400 | Jun 30, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.46% | 0.01% | 232,022 | 232,022 | 100.00% | 1,399,093 | Jun 30, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 0.20% | 0.07% | 100,000 | 100,000 | 100.00% | 603,000 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.15% | 0.01% | 75,000 | 75,000 | 100.00% | 452,250 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 0.09% | 0.00% | 44,149 | 44,149 | 100.00% | 266,218 | Jun 30, 2024 |
| ALGERT GLOBAL LLC | 0.08% | 0.01% | 41,215 | 41,215 | 100.00% | 249,000 | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | 0.07% | 0.00% | 32,571 | 32,571 | 100.00% | 196,403 | Jun 30, 2024 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 0.06% | 0.00% | 31,419 | 31,419 | 100.00% | 189,457 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.05% | 0.00% | 25,000 | 25,000 | 100.00% | 150,750 | Jun 30, 2024 |
| GRAHAM CAPITAL MANAGEMENT, L.P. | 0.05% | 0.00% | 23,942 | 23,942 | 100.00% | 144,370 | Jun 30, 2024 |
| SHERBROOKE PARK ADVISERS LLC | 0.04% | 0.02% | 22,172 | 22,172 | 100.00% | 133,697 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 0.04% | - | 21,823 | 21,823 | 100.00% | 131,593 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | 0.00% | 17,771 | 17,771 | 100.00% | 107,159 | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.03% | 0.02% | 16,402 | 16,402 | 100.00% | 98,904 | Jun 30, 2024 |
| TORNO CAPITAL, LLC | 0.03% | 0.00% | 16,000 | 16,000 | 100.00% | 96,480 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.03% | 0.00% | 13,016 | 13,016 | 100.00% | 78,486 | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | 0.03% | 0.00% | 12,600 | 12,600 | 100.00% | 75,978 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.01% | 0.00% | 6,600 | 6,600 | 100.00% | 39,798 | Jun 30, 2024 |
| STRS OHIO | 0.01% | 0.00% | 4,100 | 4,100 | 100.00% | 24,723,000 | Jun 30, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.00% | - | 2,331 | 2,331 | 100.00% | 14,055 | Jun 30, 2024 |
| POINT72 (DIFC) LTD | 0.00% | 0.00% | 1,963 | 1,963 | 100.00% | 11,836 | Jun 30, 2024 |
| SMARTLEAF ASSET MANAGEMENT LLC | 0.00% | 0.00% | 631 | 631 | 100.00% | 3,681 | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 0.00% | - | 571 | 571 | 100.00% | 3,443 | Jun 30, 2024 |
| CWM, LLC | 0.00% | - | 85 | 85 | 100.00% | 1,000 | Jun 30, 2024 |
| CREEKMUR ASSET MANAGEMENT LLC | - | - | 4 | 4 | 100.00% | 24 | Jun 30, 2024 |
ALX Oncology's largest new institutional shareholder by number of shares is PARADIGM BIOCAPITAL ADVISORS LP, purchased 1.58M shares, valued at $9.50M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORMORANT ASSET MANAGEMENT, LP | - | - | - | -3,142,079 | -100.00% | - | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | - | - | - | -160,000 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -106,356 | -100.00% | - | Jun 30, 2024 |
| LOS ANGELES CAPITAL MANAGEMENT LLC | - | - | - | -98,960 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -59,186 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -49,000 | -100.00% | - | Jun 30, 2024 |
| MARTINGALE ASSET MANAGEMENT L P | - | - | - | -36,195 | -100.00% | - | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -23,366 | -100.00% | - | Jun 30, 2024 |
| TREXQUANT INVESTMENT LP | - | - | - | -20,990 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
| BOURGEON CAPITAL MANAGEMENT LLC | - | - | - | -19,570 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -13,000 | -100.00% | - | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | - | - | - | -11,535 | -100.00% | - | Jun 30, 2024 |
| XTX TOPCO LTD | - | - | - | -10,911 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -10,289 | -100.00% | - | Jun 30, 2024 |
| FOREFRONT ANALYTICS, LLC | - | - | - | -10,261 | -100.00% | - | Jun 30, 2024 |
| FRANKLIN RESOURCES INC | - | - | - | -10,047 | -100.00% | - | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -3,514 | -100.00% | - | Jun 30, 2024 |
| ENTRYPOINT CAPITAL, LLC | - | - | - | -2,847 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -1,579 | -100.00% | - | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | - | - | - | -400 | -100.00% | - | Jun 30, 2024 |
| RED TORTOISE LLC | - | - | - | -340 | -100.00% | - | Jun 30, 2024 |
| CAPITAL ADVISORS, LTD. LLC | - | - | - | -79 | -100.00% | - | Jun 30, 2024 |
| WESTEND CAPITAL MANAGEMENT, LLC | - | - | - | -74 | -100.00% | - | Jun 30, 2024 |
| SIGNATUREFD, LLC | - | - | - | -20 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -5 | -100.00% | - | Jun 30, 2024 |
ALX Oncology's largest sold out institutional shareholder by shares sold is CORMORANT ASSET MANAGEMENT, LP, sold -3.14M shares, valued at -, as of undefined.
ALX Oncology Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| LORD ABBETT DEVELOPING GROWTH FUND, INC. | 0.53% | 494,209 | - | - | Jan 31, 2024 |
| HARTFORD HLS SERIES FUND II INC | 0.42% | 103,404 | - | - | Dec 31, 2023 |
| TEKLA LIFE SCIENCES INVESTORS | 0.14% | 66,211 | - | - | Mar 31, 2024 |
| ALGER FUNDS | 0.10% | 100,558 | - | - | Jan 31, 2024 |
| Humankind Benefit Corp | 0.09% | 2,077 | - | - | Dec 31, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.08% | 649,295 | -273,400 | -29.63% | Jan 31, 2024 |
| Federated Hermes MDT Series | 0.07% | 182,798 | -13,286 | -6.78% | Jan 31, 2024 |
| VANGUARD EXPLORER FUND | 0.04% | 548,551 | - | - | Jan 31, 2024 |
| FIDELITY SECURITIES FUND | 0.04% | 3,868,793 | 220,614 | 6.05% | Jan 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.04% | 461,800 | 45,300 | 10.88% | Jan 31, 2024 |
| BlackRock Health Sciences Trust II | 0.03% | 71,039 | - | - | Mar 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.03% | 4,955 | - | - | Mar 28, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.02% | 13,029 | - | - | Mar 31, 2024 |
| VANGUARD SPECIALIZED FUNDS | 0.02% | 978,377 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND III | 0.02% | 123,600 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.02% | 975,349 | -161,200 | -14.18% | Feb 29, 2024 |
| IndexIQ ETF Trust | 0.01% | 33,777 | - | - | Jan 31, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.01% | 86,100 | - | - | Jan 31, 2024 |
| AIM GROWTH SERIES (INVESCO GROWTH SERIES) | 0.01% | 288,728 | - | - | Mar 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.01% | 20,000 | -13,500 | -40.30% | Mar 28, 2024 |
| Gabelli Healthcare & WellnessRx Trust | 0.01% | 850 | - | - | Dec 29, 2023 |
| BNY Mellon Strategic Funds, Inc. | 0.01% | 16,118 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.01% | 4,111 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.01% | 38,942 | - | - | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.01% | 20,976 | - | - | Jan 31, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.01% | 153,787 | - | - | Feb 29, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 934,600 | -1,600 | -0.17% | Feb 29, 2024 |
| ETFis Series Trust I | 0.00% | 6,222 | -4,505 | -42.00% | Jan 31, 2024 |
| SMALLCAP WORLD FUND INC | 0.00% | 300,000 | - | - | Mar 31, 2024 |
| UBS FUNDS | 0.00% | 20,226 | - | - | Mar 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.00% | 12,852 | - | - | Feb 29, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,234,890 | -420,453 | -25.40% | Mar 31, 2024 |
| ALPS ETF Trust | 0.00% | 29,066 | - | - | Feb 29, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 515 | - | - | Mar 31, 2024 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 156,613 | 156,613 | - | Jan 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 72,542 | 12,873 | 21.57% | Jan 31, 2024 |
| Nushares ETF Trust | 0.00% | 9,690 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 251,291 | 46,659 | 22.80% | Feb 29, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 7,779 | - | - | Aug 31, 2023 |
| Direxion Shares ETF Trust | 0.00% | 171,135 | - | - | Jan 31, 2024 |
| MML SERIES INVESTMENT FUND | 0.00% | 10,401 | - | - | Dec 31, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 2,790 | - | - | Mar 31, 2024 |
| JANUS INVESTMENT FUND | 0.00% | 309,423 | - | - | Dec 31, 2023 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 3,920 | - | - | Mar 31, 2024 |
| FIDELITY COVINGTON TRUST | 0.00% | 16,876 | - | - | Feb 29, 2024 |
| Managed Portfolio Series | 0.00% | 16,935 | - | - | Jan 31, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 230,333 | 229,492 | 27287.99% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 20,243 | -1,326 | -6.15% | Mar 31, 2024 |
| PROFESSIONALLY MANAGED PORTFOLIOS | 0.00% | 48,790 | - | - | Feb 29, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 25,151 | - | - | Mar 31, 2024 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 60,613 | - | - | Mar 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 6,617 | - | - | Mar 31, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.00% | 2,000 | - | - | Mar 31, 2024 |
| Dunham Funds | 0.00% | 29,510 | - | - | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 1,052 | - | - | Mar 31, 2024 |
| HARTFORD MUTUAL FUNDS II INC | 0.00% | 58,504 | - | - | Jan 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 86,640 | 33,081 | 61.77% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 8,755 | -1,953 | -18.24% | Mar 31, 2024 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 1,293 | 306 | 31.00% | Mar 31, 2024 |
| SCHWAB STRATEGIC TRUST | 0.00% | 139,403 | 47,149 | 51.11% | Feb 29, 2024 |
| Trust for Advised Portfolios | 0.00% | 4,742 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 26,627 | 12,544 | 89.07% | Feb 29, 2024 |
| Forethought Variable Insurance Trust | 0.00% | 940 | - | - | Mar 28, 2024 |
| Global X Funds | 0.00% | 9,458 | - | - | Jan 31, 2024 |
| BlackRock ETF Trust | 0.00% | 175 | - | - | Jan 31, 2024 |
| LORD ABBETT SERIES FUND INC | 0.00% | 12,872 | - | - | Mar 31, 2024 |
| Federated Hermes Equity Funds | 0.00% | 3,000 | - | - | Jan 31, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 664,829 | - | - | Mar 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 9,900 | -800 | -7.48% | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 79 | - | - | Apr 30, 2021 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 12,111 | - | - | Mar 31, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 14,033 | 12,909 | 1148.49% | Feb 29, 2024 |
| NORTHERN FUNDS | 0.00% | 19,883 | -309 | -1.53% | Mar 28, 2024 |
| RBB FUND, INC. | 0.00% | 13,037 | - | - | Feb 29, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 1,441 | 447 | 44.97% | Mar 31, 2024 |
| Federated Hermes Global Allocation Fund | 0.00% | 1,127 | 1,127 | - | Feb 29, 2024 |
| ADVISORS' INNER CIRCLE FUND | 0.00% | 1,865 | - | - | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 1,754 | 153 | 9.56% | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 89,858 | -1,928 | -2.10% | Mar 31, 2024 |
| iSHARES TRUST | 0.00% | 1,170,073 | -52,361 | -4.28% | Mar 31, 2024 |
| OHIO NATIONAL FUND INC | 0.00% | 1,291 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 118,380 | 33,184 | 38.95% | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 24,224 | -162 | -0.66% | Jan 31, 2024 |
| GPS Funds I | 0.00% | 277 | - | - | Mar 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 197 | - | - | Dec 31, 2023 |
| SPDR SERIES TRUST | 0.00% | 1,750,207 | - | - | Mar 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 4,071 | - | - | Mar 31, 2024 |
| Chartwell Funds | 0.00% | 978 | - | - | Jun 30, 2022 |
| FIDELITY SUMMER STREET TRUST | 0.00% | 13,700 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 10,344 | 2,007 | 24.07% | Feb 29, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 4,234 | - | - | Mar 31, 2024 |
| PRUDENTIAL INVESTMENT PORTFOLIOS, INC. | 0.00% | 300 | - | - | Mar 28, 2024 |
| PROSHARES TRUST | 0.00% | 7,672 | 1,783 | 30.28% | Feb 29, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 9,143 | - | - | Jan 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 92,753 | 6,667 | 7.74% | Jan 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 1,872 | - | - | Feb 29, 2024 |
| MAINSTAY FUNDS TRUST | 0.00% | 5,461 | 5,461 | - | Jan 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 3,329 | 1,054 | 46.33% | Jan 31, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 10,006 | 9,755 | 3886.45% | Feb 29, 2024 |
| RYDEX DYNAMIC FUNDS | 0.00% | 98 | - | - | Dec 31, 2023 |
ALX Oncology's largest mutual fund holder by % of total assets is "LORD ABBETT DEVELOPING GROWTH FUND, INC.", owning 494.21K shares, compromising 0.53% of its total assets.
ALX Oncology Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 110 | -1.79% |
| 31 Mar, 24 | 112 | 14.29% |
| 31 Dec, 23 | 98 | 20.99% |
| 30 Sep, 23 | 81 | 1.25% |
| 30 Jun, 23 | 80 | -10.11% |
| 31 Mar, 23 | 89 | -1.11% |
| 31 Dec, 22 | 90 | -10.00% |
| 30 Sep, 22 | 100 | 2.04% |
| 30 Jun, 22 | 98 | 1.03% |
| 31 Mar, 22 | 97 | -9.35% |
| 31 Dec, 21 | 107 | -8.55% |
| 30 Sep, 21 | 117 | 8.33% |
| 30 Jun, 21 | 108 | 10.20% |
| 31 Mar, 21 | 98 | 10.11% |
| 31 Dec, 20 | 89 | 56.14% |
| 30 Sep, 20 | 57 | - |
As of 30 Jun 24, 110 institutions are holding ALX Oncology's shares, representing a decrease of -1.79% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 48,336,030 | 5.57% |
| 31 Mar, 24 | 45,786,300 | 0.25% |
| 31 Dec, 23 | 45,673,866 | 37.23% |
| 30 Sep, 23 | 33,283,236 | -2.95% |
| 30 Jun, 23 | 34,295,149 | -3.93% |
| 31 Mar, 23 | 35,697,671 | -2.02% |
| 31 Dec, 22 | 36,433,892 | -0.02% |
| 30 Sep, 22 | 36,439,890 | 1.41% |
| 30 Jun, 22 | 35,931,513 | -2.35% |
| 31 Mar, 22 | 36,794,795 | 1.40% |
| 31 Dec, 21 | 36,287,795 | 5.26% |
| 30 Sep, 21 | 34,475,652 | 3.50% |
| 30 Jun, 21 | 33,310,775 | -0.60% |
| 31 Mar, 21 | 33,511,219 | 3.81% |
| 31 Dec, 20 | 32,282,161 | 18.46% |
| 30 Sep, 20 | 27,250,796 | - |
ALX Oncology (ALXO) has 48.34M shares outstanding as of 30 Jun 24, up 5.57% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 96.44% | 1.16% |
| 31 Mar, 24 | 91.35% | 0.81% |
| 31 Dec, 23 | 106.25% | 1.62% |
| 30 Sep, 23 | 80.89% | 1.15% |
| 30 Jun, 23 | 83.90% | 1.10% |
| 31 Mar, 23 | 87.36% | 1.09% |
| 31 Dec, 22 | 89.40% | 1.12% |
| 30 Sep, 22 | 89.43% | 1.15% |
| 30 Jun, 22 | 88.31% | 1.08% |
| 31 Mar, 22 | 90.59% | 1.13% |
| 31 Dec, 21 | 89.54% | 1.23% |
| 30 Sep, 21 | 85.34% | 1.25% |
| 30 Jun, 21 | 82.77% | 1.18% |
| 31 Mar, 21 | 83.66% | 1.14% |
| 31 Dec, 20 | 85.76% | 1.02% |
| 30 Sep, 20 | 91.86% | - |
As of 30 Jun 24, ALX Oncology is held by 96.44% institutional shareholders, representing a 1.16% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 66 | 26.92% |
| 31 Mar, 24 | 52 | -21.21% |
| 31 Dec, 23 | 66 | 88.57% |
| 30 Sep, 23 | 35 | -5.41% |
| 30 Jun, 23 | 37 | -7.50% |
| 31 Mar, 23 | 40 | 42.86% |
| 31 Dec, 22 | 28 | -37.78% |
| 30 Sep, 22 | 45 | -18.18% |
| 30 Jun, 22 | 55 | 41.03% |
| 31 Mar, 22 | 39 | -40.91% |
| 31 Dec, 21 | 66 | 11.86% |
| 30 Sep, 21 | 59 | -4.84% |
| 30 Jun, 21 | 62 | -4.62% |
| 31 Mar, 21 | 65 | -7.14% |
| 31 Dec, 20 | 70 | 22.81% |
| 30 Sep, 20 | 57 | - |
66 institutional shareholders have increased their position in ALXO stock as of 30 Jun 24 compared to 52 in the previous quarter (a 26.92% increase).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 24 | -22.58% |
| 31 Mar, 24 | 31 | 93.75% |
| 31 Dec, 23 | 16 | -30.43% |
| 30 Sep, 23 | 23 | 27.78% |
| 30 Jun, 23 | 18 | -33.33% |
| 31 Mar, 23 | 27 | -18.18% |
| 31 Dec, 22 | 33 | 3.13% |
| 30 Sep, 22 | 32 | 52.38% |
| 30 Jun, 22 | 21 | -41.67% |
| 31 Mar, 22 | 36 | 63.64% |
| 31 Dec, 21 | 22 | -35.29% |
| 30 Sep, 21 | 34 | 36.00% |
| 30 Jun, 21 | 25 | 47.06% |
| 31 Mar, 21 | 17 | 88.89% |
| 31 Dec, 20 | 9 | - |
| 30 Sep, 20 | - | - |
24 institutional shareholders have reduced their position in ALXO stock as of 30 Jun 24 compared to 31 in the previous quarter (a -22.58% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 110 | -1.79% | 48,336,030 | 5.57% | 96.44% | 1.16% | 66 | 26.92% | 24 | -22.58% |
| 31 Mar, 24 | 112 | 14.29% | 45,786,300 | 0.25% | 91.35% | 0.81% | 52 | -21.21% | 31 | 93.75% |
| 31 Dec, 23 | 98 | 20.99% | 45,673,866 | 37.23% | 106.25% | 1.62% | 66 | 88.57% | 16 | -30.43% |
| 30 Sep, 23 | 81 | 1.25% | 33,283,236 | -2.95% | 80.89% | 1.15% | 35 | -5.41% | 23 | 27.78% |
| 30 Jun, 23 | 80 | -10.11% | 34,295,149 | -3.93% | 83.90% | 1.10% | 37 | -7.50% | 18 | -33.33% |
| 31 Mar, 23 | 89 | -1.11% | 35,697,671 | -2.02% | 87.36% | 1.09% | 40 | 42.86% | 27 | -18.18% |
| 31 Dec, 22 | 90 | -10.00% | 36,433,892 | -0.02% | 89.40% | 1.12% | 28 | -37.78% | 33 | 3.13% |
| 30 Sep, 22 | 100 | 2.04% | 36,439,890 | 1.41% | 89.43% | 1.15% | 45 | -18.18% | 32 | 52.38% |
| 30 Jun, 22 | 98 | 1.03% | 35,931,513 | -2.35% | 88.31% | 1.08% | 55 | 41.03% | 21 | -41.67% |
| 31 Mar, 22 | 97 | -9.35% | 36,794,795 | 1.40% | 90.59% | 1.13% | 39 | -40.91% | 36 | 63.64% |
| 31 Dec, 21 | 107 | -8.55% | 36,287,795 | 5.26% | 89.54% | 1.23% | 66 | 11.86% | 22 | -35.29% |
| 30 Sep, 21 | 117 | 8.33% | 34,475,652 | 3.50% | 85.34% | 1.25% | 59 | -4.84% | 34 | 36.00% |
| 30 Jun, 21 | 108 | 10.20% | 33,310,775 | -0.60% | 82.77% | 1.18% | 62 | -4.62% | 25 | 47.06% |
| 31 Mar, 21 | 98 | 10.11% | 33,511,219 | 3.81% | 83.66% | 1.14% | 65 | -7.14% | 17 | 88.89% |
| 31 Dec, 20 | 89 | 56.14% | 32,282,161 | 18.46% | 85.76% | 1.02% | 70 | 22.81% | 9 | - |
| 30 Sep, 20 | 57 | - | 27,250,796 | - | 91.86% | - | 57 | - | - | - |
ALX Oncology Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
All Insider Owners Trades
The last insider sell of ALX Oncology's stock was made by Pinto Shelly on Aug 16 2024, selling 564 shares at $2.58 per share (valued at $1.46K). The last insider buy of ALXO was made by GARCIA PETER S on Jun 17 2024, buying 12,000 shares at $8.53 per share (worth $102.34K).
ALX Oncology Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 2 | 11 | 18.18% |
| Q2 2024 | 7 | 10 | 70.00% |
| Q1 2024 | 11 | 1 | 1100.00% |
| Q4 2023 | - | 4 | - |
| Q3 2023 | 9 | 1 | 900.00% |
| Q2 2023 | 9 | 7 | 128.57% |
| Q4 2022 | 4 | 7 | 57.14% |
| Q3 2022 | 6 | - | - |
| Q2 2022 | 8 | - | - |
| Q1 2022 | 5 | 4 | 125.00% |
| Q4 2021 | 4 | 73 | 5.48% |
| Q3 2021 | 8 | 46 | 17.39% |
| Q2 2021 | 6 | 22 | 27.27% |
| Q1 2021 | 4 | 15 | 26.67% |
| Q4 2020 | 1 | - | - |
| Q3 2020 | 42 | 40 | 105.00% |
| Q2 2020 | 1 | - | - |
2 total buy trades, and 11 total sell trades (buy/sell ratio of 0.18%) were made by ALX Oncology's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 8 | - |
| Q2 2024 | 1 | 6 | 16.67% |
| Q1 2024 | 1 | 1 | 100.00% |
| Q4 2023 | - | 4 | - |
| Q3 2023 | - | 1 | - |
| Q2 2023 | - | 4 | - |
| Q4 2022 | - | 4 | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | - | - | - |
| Q4 2021 | - | 69 | - |
| Q3 2021 | - | 41 | - |
| Q2 2021 | - | 22 | - |
| Q1 2021 | - | 11 | - |
| Q4 2020 | 1 | - | - |
| Q3 2020 | 13 | - | - |
| Q2 2020 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 8 open market sell trades of ALX Oncology's stocks.
ALX Oncology Peer Ownership
| Ticker | Company |
|---|---|
| CGEM | Cullinan Oncology, Inc. |
| DYN | Dyne Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| EYPT | EyePoint Pharmaceuticals, Inc. |
| BCAB | BioAtla, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| BMEA | Biomea Fusion, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| IMTX | Immatics N.V. |
| BDTX | Black Diamond Therapeutics, Inc. |
| BCEL | Atreca, Inc. |
| VIRX | Viracta Therapeutics, Inc. |
| PASG | Passage Bio, Inc. |
| CABA | Cabaletta Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
ALXO Ownership FAQ
Who Owns ALX Oncology?
ALX Oncology is owned by institutional shareholders (96.44%), insiders (1.92%), and public (1.65%). The largest institutional shareholder of ALX Oncology is VENBIO PARTNERS LLC (19.35% of total shares) and the top mutual fund owner is LORD ABBETT DEVELOPING GROWTH FUND, INC. (0.53% of total shares).
Who are the major institutional shareholders of ALX Oncology?
ALX Oncology's major institutional shareholders are VENBIO PARTNERS LLC, FMR LLC, VIVO CAPITAL, LLC, REDMILE GROUP, LLC, and VESTAL POINT CAPITAL, LP. The top five shareholders own together 58.60% of the company's share outstanding.
How many ALX Oncology shareholders are there?
As of Jun 2024, there are 110 institutional shareholders of ALX Oncology.
What percentage of ALX Oncology is owned by VENBIO PARTNERS LLC?
VENBIO PARTNERS LLC owns 9.7M shares of ALX Oncology, representing 19.35% of the company's total shares outstanding, valued at $58.49M (as of Jun 2024).
What percentage of ALX Oncology is owned by FMR LLC?
As of Jun 2024, FMR LLC holds 7.81M shares of ALX Oncology (ALXO), compromising 15.59% of the company, valued at $47.12M.
What percentage of ALX Oncology is owned by VIVO CAPITAL, LLC?
VIVO CAPITAL, LLC is the third largest holder of ALX Oncology. The company owns 4.22M of the company's shares outstanding (worth $25.45M).